RMTG (Regenerative Medical Technology Group) EV-to-FCF: -20.59 (As of Jun. 27, 2026)
What is Regenerative Medical Technology Group EV-to-FCF?
Regenerative Medical Technology GroupRMTG EV-to-FCF is -20.59 as of Jun. 27, 2026. The stock has 4 warning signs investors should review. Among 333 Biotechnology companies, Regenerative Medical Technology Group ranks worse than 300300% on this metric.
RMTG'
s EV-to-FCF Range Over the Past 10 Years
Min: -2453.36 Med: -7.8 Max: 2872.42
Current: -20.59
During the past 9 years, the highest EV-to-FCF of Regenerative Medical Technology Group was 2872.42. The lowest was -2453.36. And the median was -7.80.
RMTG's EV-to-FCF is ranked worse than 100% of 333
companies
in the Biotechnology industry
Industry Median: 14.65
vs RMTG: -20.59
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Regenerative Medical Technology Group (OTCPK:RMTG) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Regenerative Medical Technology Group's PE Ratio (TTM) for today is calculated as:
Regenerative Medical Technology Group's share price for today is $0.0452.
Regenerative Medical Technology Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.630.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Regenerative Medical Technology Group EV-to-FCF Related Terms
Regenerative Medical Technology Group EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group EV-to-FCF Chart
For the Biotechnology subindustry, Regenerative Medical Technology Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regenerative Medical Technology Group EV-to-FCF vs Biotechnology Industry
Regenerative Medical Technology Group's current Enterprise Value is $20.11 Mil.
Regenerative Medical Technology Group's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Regenerative Medical Technology Group (RMTG) has a EV-to-FCF of -20.59 as of Jun. 27, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Regenerative Medical Technology Group and its competitors. According to the industry distribution chart, Regenerative Medical Technology Group ranks #999999 out of 333 companies in the Biotechnology industry.
Is Regenerative Medical Technology Group's EV-to-FCF too high?
Regenerative Medical Technology Group's current EV-to-FCF is -20.59. Based on the distribution chart, Regenerative Medical Technology Group ranks #999999 out of 333 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Regenerative Medical Technology Group's EV-to-FCF compare to WINT and LIPO?
According to the Biotechnology industry distribution chart, Regenerative Medical Technology Group ranks #999999 out of 333 companies for EV-to-FCF. This places Regenerative Medical Technology Group in the lower half of its industry. The industry median EV-to-FCF is 14.65. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.65, based on 333 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Regenerative Medical Technology Group and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regenerative Medical Technology Group's current EV-to-FCF is -20.59. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenerative Medical Technology Group stock overvalued right now?
Based on GuruFocus' analysis, Regenerative Medical Technology Group (RMTG) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.06, compared to a current price of $0.05 — trading 24.7% below its estimated fair value. The current EV-to-FCF is -20.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Regenerative Medical Technology Group (RMTG), the current EV-to-FCF is -20.59 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Regenerative Medical Technology Group Business Description
Regenerative Medical Technology Group Inc is engaged in the regenerative medicine business through its subsidiary, Global Stem Cells Group. The company provides stem cell therapies, exosomes, peptides, biologics, physician training and certifications, diagnostic tools, and related clinical support services. It operates through one reportable segment, Global Stem Cells Group.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RMTG has been successfully added to your 